These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274 [TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698 [TBL] [Abstract][Full Text] [Related]
49. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Gibbs JP; Murray G; Risler L; Chien JY; Dev R; Slattery JT Cancer Res; 1997 Dec; 57(24):5509-16. PubMed ID: 9407960 [TBL] [Abstract][Full Text] [Related]
50. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Ferrara F; Palmieri S; De Simone M; Sagristani M; Viola A; Pocali B; Fasanaro A; Mele G Br J Haematol; 2005 Jan; 128(2):234-41. PubMed ID: 15638859 [TBL] [Abstract][Full Text] [Related]
51. The use of busulfan therapy in bone marrow transplantation. A nursing overview. Rohaly J Cancer Nurs; 1989 Jun; 12(3):144-52. PubMed ID: 2663138 [TBL] [Abstract][Full Text] [Related]
52. High dose busulfan and seizures. De La Camara R; Tomas JF; Figuera A; Berberana M; Fernandez-Rañada JM Bone Marrow Transplant; 1991 May; 7(5):363-4. PubMed ID: 2070145 [TBL] [Abstract][Full Text] [Related]
53. [The treatment of chronic leukemia in children]. Koshel' IV Pediatriia; 1966 Oct; 45(10):15-8. PubMed ID: 5239925 [No Abstract] [Full Text] [Related]
54. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320 [TBL] [Abstract][Full Text] [Related]
55. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. Benadiba J; Ansari M; Krajinovic M; Vachon MF; Duval M; Teira P; Cellot S; Bittencourt H PLoS One; 2018; 13(4):e0193862. PubMed ID: 29608607 [TBL] [Abstract][Full Text] [Related]
58. Platelet function after busulphan in chronic myeloproliferative disorders. Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897 [No Abstract] [Full Text] [Related]
59. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112 [TBL] [Abstract][Full Text] [Related]
60. An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung. Stott H; Stephens R; Fox W; Simon G; Roy DC Thorax; 1976 Jun; 31(3):265-70. PubMed ID: 781905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]